Comparative Pharmacology
Head-to-head clinical analysis: LIQREV versus NUTRILIPID 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQREV versus NUTRILIPID 10.
LIQREV vs NUTRILIPID 10%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Nutrilipid 10% is a fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. It serves as a component of parenteral nutrition, supplying triglycerides that are metabolized to free fatty acids and glycerol for energy production and cellular functions.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
Intravenous infusion, 1-2 g/kg/day (0.5-1 g/kg/day for 10% emulsion), not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 15-30 minutes, then increase to maximum of 125 mL/hour.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Terminal elimination half-life: approximately 0.5-1 hour for the triglyceride component in healthy adults; clinically, clearance depends on infusion rate and metabolic capacity, with prolonged half-life in hypertriglyceridemia.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Renal: negligible; biliary/fecal: not applicable as lipid emulsion is metabolized; elimination primarily via lipoprotein lipase-mediated clearance from plasma.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion